Biosurgical Agents | Market Insights | US | 2018
The US market for biosurgical agents is driven in large part by the ongoing shift toward value-based care and the growing influence of GPOs in the US, which have placed increased emphasis on device efficacy and cost-effectiveness. The clinical benefits of these products, coupled with growing surgical volumes in the country, will drive unit sales, while growing concerns over product cost will limit ASP growth in this market to some extent. Together, these forces will allow the market to grow moderately throughout the forecast period, presenting a lucrative opportunity for competitors in this space.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the US across a 10-year period.
